229 related articles for article (PubMed ID: 14645148)
1. Why is parkinsonism not a feature of human methamphetamine users?
Moszczynska A; Fitzmaurice P; Ang L; Kalasinsky KS; Schmunk GA; Peretti FJ; Aiken SS; Wickham DJ; Kish SJ
Brain; 2004 Feb; 127(Pt 2):363-70. PubMed ID: 14645148
[TBL] [Abstract][Full Text] [Related]
2. Brain antioxidant systems in human methamphetamine users.
Mirecki A; Fitzmaurice P; Ang L; Kalasinsky KS; Peretti FJ; Aiken SS; Wickham DJ; Sherwin A; Nobrega JN; Forman HJ; Kish SJ
J Neurochem; 2004 Jun; 89(6):1396-408. PubMed ID: 15189342
[TBL] [Abstract][Full Text] [Related]
3. Brain vesicular acetylcholine transporter in human users of drugs of abuse.
Siegal D; Erickson J; Varoqui H; Ang L; Kalasinsky KS; Peretti FJ; Aiken SS; Wickham DJ; Kish SJ
Synapse; 2004 Jun; 52(4):223-32. PubMed ID: 15103689
[TBL] [Abstract][Full Text] [Related]
4. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
[TBL] [Abstract][Full Text] [Related]
5. Chronic stress augments the long-term and acute effects of methamphetamine.
Matuszewich L; Yamamoto BK
Neuroscience; 2004; 124(3):637-46. PubMed ID: 14980734
[TBL] [Abstract][Full Text] [Related]
6. Intermittent Dopaminergic stimulation causes behavioral sensitization in the addicted brain and parkinsonism.
Fornai F; Biagioni F; Fulceri F; Murri L; Ruggieri S; Paparelli A
Int Rev Neurobiol; 2009; 88():371-98. PubMed ID: 19897084
[TBL] [Abstract][Full Text] [Related]
7. Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.
Kish SJ; Boileau I; Callaghan RC; Tong J
Eur J Neurosci; 2017 Jan; 45(1):58-66. PubMed ID: 27519465
[TBL] [Abstract][Full Text] [Related]
8. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss.
Kish SJ; Rajput A; Gilbert J; Rozdilsky B; Chang LJ; Shannak K; Hornykiewicz O
Ann Neurol; 1986 Jul; 20(1):26-31. PubMed ID: 2874765
[TBL] [Abstract][Full Text] [Related]
9. Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment.
Volz TJ; Fleckenstein AE; Hanson GR
Addiction; 2007 Apr; 102 Suppl 1():44-8. PubMed ID: 17493052
[TBL] [Abstract][Full Text] [Related]
10. Is brain gliosis a characteristic of chronic methamphetamine use in the human?
Tong J; Fitzmaurice P; Furukawa Y; Schmunk GA; Wickham DJ; Ang LC; Sherwin A; McCluskey T; Boileau I; Kish SJ
Neurobiol Dis; 2014 Jul; 67():107-18. PubMed ID: 24704312
[TBL] [Abstract][Full Text] [Related]
11. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse.
Chang L; Alicata D; Ernst T; Volkow N
Addiction; 2007 Apr; 102 Suppl 1():16-32. PubMed ID: 17493050
[TBL] [Abstract][Full Text] [Related]
12. Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge.
O'Neil ML; Kuczenski R; Segal DS; Cho AK; Lacan G; Melega WP
Synapse; 2006 Nov; 60(6):465-73. PubMed ID: 16897726
[TBL] [Abstract][Full Text] [Related]
13. Single or multiple injections of methamphetamine increased dopamine turnover but did not decrease tyrosine hydroxylase levels or cleave caspase-3 in caudate-putamen.
Pereira FC; Lourenço ES; Borges F; Morgadinho T; Ribeiro CF; Macedo TR; Ali SF
Synapse; 2006 Sep; 60(3):185-93. PubMed ID: 16739116
[TBL] [Abstract][Full Text] [Related]
14. Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users.
Tong J; Ross BM; Schmunk GA; Peretti FJ; Kalasinsky KS; Furukawa Y; Ang LC; Aiken SS; Wickham DJ; Kish SJ
Am J Psychiatry; 2003 May; 160(5):896-903. PubMed ID: 12727693
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure.
Bowyer JF; Robinson B; Ali S; Schmued LC
Synapse; 2008 Mar; 62(3):193-204. PubMed ID: 18081184
[TBL] [Abstract][Full Text] [Related]
16. Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study.
Nordahl TE; Salo R; Natsuaki Y; Galloway GP; Waters C; Moore CD; Kile S; Buonocore MH
Arch Gen Psychiatry; 2005 Apr; 62(4):444-52. PubMed ID: 15809412
[TBL] [Abstract][Full Text] [Related]
17. Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum.
Theodore S; Cass WA; Maragos WF
Neuroscience; 2006 Feb; 137(3):925-35. PubMed ID: 16338084
[TBL] [Abstract][Full Text] [Related]
18. Methamphetamine-induced loss of striatal dopamine innervation in BDNF heterozygote mice does not further reduce D3 receptor concentrations.
Joyce JN; Renish L; Osredkar T; Walro JM; Kucera J; Dluzen DE
Synapse; 2004 Apr; 52(1):11-9. PubMed ID: 14755628
[TBL] [Abstract][Full Text] [Related]
19. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428.
McCann UD; Wong DF; Yokoi F; Villemagne V; Dannals RF; Ricaurte GA
J Neurosci; 1998 Oct; 18(20):8417-22. PubMed ID: 9763484
[TBL] [Abstract][Full Text] [Related]
20. Methamphetamine and cardiovascular pathology: a review of the evidence.
Kaye S; McKetin R; Duflou J; Darke S
Addiction; 2007 Aug; 102(8):1204-11. PubMed ID: 17565561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
